Recent research has demonstrated that users of GLP-1 receptor agonists exhibit a significantly higher likelihood of experiencing nail disorders, particularly onycholysis, compared to non-users. In a large prospective study, it was observed that 39.3% of 575 participants using GLP-1 agonists reported onycholysis, in contrast to only 8.7% of obese or diabetic patients not undergoing this treatment. This translates to a 4.5-fold increase in risk for nail separation among users of the medication.
Nail Disorders and GLP-1 Agonists
The study results indicated that 45.6% of GLP-1 users also experienced dyschromia, or nail discoloration, compared to 17.0% in the control group, resulting in a 2.7-fold greater likelihood for this condition as well. Other nail issues, such as fragility and the presence of ridges or grooves, were also more frequently reported among those on GLP-1 therapy.
Overall, 66.3% of GLP-1 users experienced some form of nail disorder, a statistically significant difference compared to 52.8% of non-users (p<0.001). Even after adjusting for comorbidities and dermatologic conditions, the analysis revealed a persistent increase in the likelihood of onycholysis and dyschromia among those using GLP-1 agonists, with findings remaining consistent even in weight-loss-specific analyses.
Previous Nail Issues
Notably, almost half of the participants on GLP-1 receptor agonists reported having prior nail problems before starting treatment. Sensitivity analysis suggested that the increased rates of onycholysis and dyschromia in GLP-1 users continued to hold true despite this history. However, no significant differences were observed in new-onset nail conditions between users and non-users of these medications.
Dr. Bianca Maria Piraccini, leading the study from the University of Bologna, emphasized that onycholysis is particularly puzzling as it cannot generally be attributed to weight loss alone, suggesting a potential direct link to the medication.
Clinical Implications
For healthcare providers managing patients on GLP-1 receptor agonists, Dr. Piraccini advises vigilance in monitoring nail health, encouraging clinicians to inquire about pre-existing nail conditions and closely assess the nails throughout the treatment.
Dr. Charles Taieb, a co-investigator, noted this study as one of the first large-scale analyses focusing on the effects of GLP-1 receptor agonists on nails and hair, emphasizing the importance of differentiating between drug-induced changes and pre-existing conditions.
Expert Perspective
In light of these findings, Dr. Joe Tung cautions against over-interpretation. He highlighted that while an initial glance at the data indicated a higher incidence of nail problems among GLP-1 users, these associations diminished when considering other health factors and self-reported data. He suggests that individuals experiencing nail changes should consult a dermatologist to investigate treatable underlying causes.
Study Details and Outcomes
The study included participants from multiple countries, comparing 575 users of GLP-1 receptor agonists to a control group of 1,329 individuals with obesity and/or type 2 diabetes who had never used these drugs. Adjusted analyses consistently showed significant odds ratios for both onycholysis and dyschromia, warranting further investigation into the potential effects of GLP-1 medications on nail health.
Disclaimer: The information provided is for educational purposes only and should not be considered medical advice. Always consult a healthcare professional for a diagnosis or treatment options.
Fuente: https://www.medpagetoday.com/meetingcoverage/eadv/123238
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
